With the help of state legislators, physicians in Philadelphia have something to celebrate.
Small mpMRI index lesions are favorable marker for guiding active surveillance strategies
Small index lesions on initial multiparametric MRI were linked to a less aggressive clinical course for patients with prostate cancer on active surveillance.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Blue light cystoscopy significantly decreases risk of recurrence in NMIBC
The investigators reported that “the risk of recurrence was significantly lower following BLC (HR=0.67, 95% CI: 0.51-0.89) than WLC.”
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
FDA grants priority review to frontline enfortumab vedotin plus pembrolizumab for urothelial carcinoma
The priority review is based on results from the phase 3 EV-302 trial.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.
2 Clarke Drive Cranbury, NJ 08512